Back to Search
Start Over
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFRT790M-Mutated NSCLC That Had Progressed After Prior EGFRTyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
- Source :
- Journal of Thoracic Oncology; October 2022, Vol. 17 Issue: 10 p1192-1204, 13p
- Publication Year :
- 2022
-
Abstract
- Befotertinib (D-0316) is a novel, third-generation EGFRtyrosine kinase inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or metastatic NSCLC who developed an EGFRT790M mutation after progression on first- or second-generation EGFRTKI therapy.
Details
- Language :
- English
- ISSN :
- 15560864 and 15561380
- Volume :
- 17
- Issue :
- 10
- Database :
- Supplemental Index
- Journal :
- Journal of Thoracic Oncology
- Publication Type :
- Periodical
- Accession number :
- ejs60216075
- Full Text :
- https://doi.org/10.1016/j.jtho.2022.06.002